Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
Incidence of diabetes mellitus following hospitalisation for COVID‐19 in the United Kingdom: A prospective observational study
Tyrer F. et al, (2025), Diabetes, Obesity and Metabolism, 27, 767 - 776
Reply to: “Understanding virologic heterogeneity in chronic hepatitis B treatment”
Matthews PC. et al, (2025), JHEP Reports, 7, 101280 - 101280
TomoCPT: a generalizable model for 3D particle detection and localization in cryo-electron tomograms
Shah PNM. et al, (2025), Acta Crystallographica Section D Structural Biology, 81, 63 - 76
Acute rheumatic fever in the UK and Ireland: a BPSU surveillance study
Gourlay-Gudex M. et al, (2025), Archives of Disease in Childhood
Exploitation of Unconventional CD8 T-Cell Responses Induced by Engineered Cytomegaloviruses for the Development of an HIV-1 Vaccine
Bruton J. and Hanke T., (2025), Vaccines, 13, 72 - 72
Quantifying potential immortal time bias in observational studies in acute severe infection
Yates TA. et al, (2025)
In vivo enhancement of tumour-specific T cells via peptide–MHC-pseudotyped retroviral gene delivery
Kwong H. and Borrow P., (2025), Nature Reviews Immunology
A diagnostic host-specific transcriptome response for Mycoplasma pneumoniae pneumonia to guide pediatric patient treatment.
Viz-Lasheras S. et al, (2025), Nature communications, 16
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials
Venkatraman N. et al, (2025), The Lancet Microbe, 100868 - 100868
Identifying falsified COVID-19 vaccines by analysing vaccine vial label and excipient profiles using MALDI-ToF mass spectrometry.
Arman BY. et al, (2025), NPJ vaccines, 10
Long term health outcomes in people with diabetes 12 months after hospitalisation with COVID-19 in the UK: a prospective cohort study.
Gharibzadeh S. et al, (2025), EClinicalMedicine, 79
Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial
Conlin K. et al, (2025), Vaccine, 45, 126582 - 126582
Recombinant expression systems for production of stabilised virus-like particles as next-generation polio vaccines.
Sherry L. et al, (2025), Nature communications, 16
Routine childhood rabies pre-exposure prophylaxis can be cost effective in low- and middle-income countries.
Ritchie AJ. et al, (2025), Vaccine, 47
Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study.
Feng S. et al, (2025), The Journal of infection, 90
Strong immune responses and robust protection following a novel protein in adjuvant tuberculosis vaccine candidate.
Korompis M. et al, (2025), Scientific reports, 15
The R21/Matrix-M malaria vaccine: questions remain - Author's reply.
Datoo MS. et al, (2025), Lancet (London, England), 405, 299 - 301
Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines.
Stockdale LK. et al, (2025), NPJ vaccines, 10
Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adults
Silman D. et al, (2024), Wellcome Open Research, 9, 734 - 734